• news.cision.com/
  • 2cureX/
  • COVID-19 precautions: Remote setup secure continued sample screening supporting cancer patients
English

COVID-19 precautions: Remote setup secure continued sample screening supporting cancer patients

Report this content

2cureX has taken the necessary precautions in relation to the COVID-19 outbreak. These will not change the outlook for 2cureX’s coming market launch of IndiTreat.

In accordance with the Danish government's recommendations, 2cureX has decided that those functions where it’s possible to work from home, will do so. Critical functions that support our laboratory activities will work in rotation in order to have uninterrupted delivery to our clinical and commercial partners. This exceptional situation is expected to be maintained until further guidance from the Danish Health ministry. Partners, customers and investors can continue to interact with 2cureX through the usual channels.

CEO Ole Thastrup comments:” This change in work conditions for our employees will not influence our plans for launching IndiTreat in the second half of 2020.  Further, we continue to screen patient samples as they come in”.

Ole Thastrup adds: “We are in close contact with our clinical and commercial partners. Considering the current Corona Virus crisis, it is important to keep in mind that the biggest challenge for the healthcare system still is to effectively treat cancer patients.

We support and hope that the dramatic measures instigated by the Danish government will have a positive influence on the spread of the virus”.

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com

-------

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumours that are similar to the patient’s tumour and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and The United Kingdom.

IndiTreat® is presently being introduced into the European market through an Early Access Program. 

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).

Documents & Links